<scp>L</scp>‐DOPA‐Coated Manganese Oxide Nanoparticles as Dual MRI Contrast Agents and Drug‐Delivery Vehicles

McDonagh, Birgitte Hjelmeland; Singh, Gurvinder; Hak, Sjoerd; Bandyopadhyay, Sulalit; Augestad, Ingrid Lovise; Peddis, Davide; Sandvig, Ioanna; Sandvig, Axel; Glomm, Wilhelm R.

doi:10.1002/smll.201502545

Cited by 83 publications

(49 citation statements)

References 56 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal carcinoma T 1 MR imaging was accomplished by Li et al, targeting MnO NPs using AS1411 aptamer [24]. Manganese oxide NPs have also been used as theranostic platforms for drug delivery and photothermal therapy at the tumour site [25][26][27]. MnO NPs have served as a platform to synthesise hybrid molecular imaging probes for both PET (Positron Emission Tomography)/MRI for tumour vasculature imaging using 64 Cu [28] and fluorescence/MRI with Cy7.5 for lymph node mapping [29].…”

Section: Paramagnetic Mno Nanoparticlesmentioning

confidence: 99%

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

et al. 2020

View full text Add to dashboard Cite

Iron oxide nanoparticles have been extensively utilised as negative (T2) contrast agents in magnetic resonance imaging. In the past few years, researchers have also exploited their application as positive (T1) contrast agents to overcome the limitation of traditional Gd3+ contrast agents. To provide T1 contrast, these particles must present certain physicochemical properties with control over the size, morphology and surface of the particles. In this review, we summarise the reported T1 iron oxide nanoparticles and critically revise their properties, synthetic protocols and application, not only in MRI but also in multimodal imaging. In addition, we briefly summarise the most important nanoparticulate Gd and Mn agents to evaluate whether T1 iron oxide nanoparticles can reach Gd/Mn contrast capabilities.

show abstract

Section: Paramagnetic Mno Nanoparticlesmentioning

confidence: 99%

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Bi-magnetic nanocomposites and low-dimensional materials (e.g., core-shell systems) are of huge scientific and technological interest, and can be used in a variety of applications, such as in biomedicine and catalysis, [1][2][3][4][5][6][7][8][9] for electromagnetic functions such as electromagnetic wave absorption and shielding, [10][11][12] and improving functional properties such as obtaining room temperature giant magnetoresistance. 13 The wide range of possible applications has triggered intense research activities in the field in recent years.…”

Section: Introductionmentioning

confidence: 99%

Controlling magnetic coupling in bi-magnetic nanocomposites

et al. 2019

View full text Add to dashboard Cite

show abstract

“…27,28 Moreover, the released transition metal ions within the process of degradation are very efficient T 1 contrast agents. 29,30 According to previous reports, Co 3 O 4 nanoparticles were feasible for MRI as T 2 contrast agent, while the ionic degradation product Co 2+ had potential for T 1 -weighted MRI. 31,32 Thus, the designed degradable Co 3 O 4 -based nanocarriers can potentially offer a very useful technique to monitor the controlled degradation and drug release simultaneously by the time-dependent T 2 to T 1 contrast switching.…”

Section: Introductionmentioning

confidence: 90%

Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy

Yun

Liu²,

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundUtilizing the permeability enhancement and irreversible biomolecule denaturation caused by hyperthermia, photothermal-chemo synergistic therapy has shown great potential in clinical cancer treatment.PurposeThe objective of this study was to provide a novel controlled drug release method to improve the efficiency of photothermal-chemo synergistic therapy.Patients and methodsHCT116 tumor-bearing mice were selected as modal for the study of cancer theranostics efficiency. The T2 to T1 magnetic resonance imaging contrast switch was studied in vivo. Analyses of the tumor growth of mice were carried out to evaluate the tumor therapy efficiency.ResultsWe developed novel artificially controlled degradable Co3O4 nanoparticles and explored their potential in drug delivery/release. In the presence of ascorbic acid (AA), the designed nanomaterials can be degraded via a redox process and hence release the loaded drugs. Importantly, the AA, in the lack of l-gulonolactone oxidase, cannot be synthesized in the body of typical mammal including human, which suggested that the degradation process can be controlled artificially. Moreover, the obtained nanoparticles have outstanding photothermal conversion efficiency and their degradation can also result in an magnetic resonance imaging contrast enhancement switch from T2 to T1, which benefits the cancer theranostics.ConclusionOur results illustrated that the artificially controlled degradable nanoparticles can serve as an alternative candidate for controllable drug release as well as a platform for highly efficient photothermal-chemo synergistic cancer theranostics.

show abstract

L‐DOPA‐Coated Manganese Oxide Nanoparticles as Dual MRI Contrast Agents and Drug‐Delivery Vehicles

Cited by 83 publications

References 56 publications

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

Controlling magnetic coupling in bi-magnetic nanocomposites

Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy

Contact Info

Product

Resources

About